Sunshine Biopharma Parent Company Receives $510,000 Research Grant for Adva-27a Cancer Drug Candidate, Brings Total to $1.45 ...
August 12 2013 - 8:00AM
Marketwired
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company
focused on the research, development and commercialization of drugs
for the treatment of various forms of cancer, today announced that
its parent company, Advanomics Corporation, has been awarded a
second research grant, this time from Canadian Institutes of Health
Research (CIHR), to advance the development of Adva-27a, the
Company's flagship anticancer drug candidate in development for
multidrug resistant cancers. The grant, in the amount of $510,000,
was awarded to Advanomics Corporation in collaboration with Ecole
Polytechnique.
On July 16, the Company announced a research grant from NSERC
and NanoQuebec in the amount of $940,000, bringing the total grants
received from these distinguished agencies for the development of
Adva-27a to $1.45 million.
"We are extremely pleased to have garnered this support from
CIHR in addition to the support from NSERC and NanoQuebec to
develop our novel cancer drug," said Dr. Steve N. Slilaty, CEO of
Sunshine Biopharma. "Their commitment will prove invaluable in the
advancement of Adva-27a and provides us a strong foundation for
clinical trials."
About Adva-27a Adva-27a is Advanomics
Corporation's and Sunshine Biopharma's lead anticancer compound, a
small molecule that has recently been shown to be effective at
killing multidrug resistant breast cancer cells, small-cell lung
cancer cells, uterine sarcoma cells and pancreatic cancers cells
(Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432,
October 2012). Adva-27a is currently in the IND-Enabling stage of
development. The original US patent covering Adva-27a was issued on
August 7, 2012 under US patent number 8,236,935.
About Advanomics Corporation Advanomics
Corporation is a privately held Canadian company (55% shareholder
of Sunshine Biopharma Inc.) focused on the research and development
of treatments for cancer and other human diseases. Advanomics is
conducting research and development in the areas of siRNA and
Carbon-Difluoride Chemistry to generate novel anticancer
compounds.
Safe Harbor Forward-Looking Statements To
the extent that statements in this press release are not strictly
historical, including statements as to revenue projections,
business strategy, outlook, objectives, future milestones, plans,
intentions, goals, future financial conditions, future
collaboration agreements, the success of the Company's development,
events conditioned on stockholder or other approval, or otherwise
as to future events, such statements are forward-looking, and are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. The forward-looking
statements contained in this release are subject to certain risks
and uncertainties that could cause actual results to differ
materially from the statements made.
For Additional Information Contact: Camille Sebaaly CFO
Sunshine Biopharma Inc. Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com www.sunshinebiopharma.com